United Kingdom (UK)
Recombinant monoclonal antibody to CEA. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 806.077.
UniProt Accession Number of Target Protein: Q13984
Alternative Name(s) of Target: carcinoembryonic antigen; Accession No. 96022936
Immunogen: The original antibody was generated by immunizing BALB/C mice with CEA. The antibody was subsequently humanized.
Specificity: The antibody is selective for CEA, exhibiting no cross reactivity to granulocytes.
Application Notes: The antibody-CPG2 conjugate showed anti-tumour activity in an ADEPT model. The antibody was employed to screen human normal and tumour tissues using sensitive three-stage indirect immunohistology on acetone-fixed, frozen cryostat sections. Further, the reactivity of the antibody was compared against A5B7. The two antibodies showed comparable results in the following tumours: colon tumours, NSCLC tumours, gastric tumours. The anti-tumour activity of the F(ab′)2-CPG2 conjugate antibody was evaluated in combination with the prodrug N(4-[N,N-bis(2-chloroethyl)amino]-phenoxycarbonyl)-L-glutamic acid in a human colorectal tumour xenograft model. The results demonstrated that the F(ab′)2-CPG2 conjugate antibody in combination with the PGP prodrug produced tumour regressions and prolonged growth delays which were statistically significant compared with control groups. The humanized version of the parental mouse antibody was also constructed (US6903203B2).
Antibody first published in: PMID: